VRDN compared with CTMX: revenue, margins and what each company keeps, and the suppliers and customers both name

VRDNViridian Therapeutics, Inc.

Mkt capRevenueRevenue

CTMXCytomX Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

VRDNViridian Therapeutics, Inc.

CTMXCytomX Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

VRDN

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.2%▲+6.83%×0.40

May 5 '26±9.5%▲+33.36%×3.52

Q1 FY26±24.8%▲+1.90%×0.08

Nov 5 '25±18.1%▲+8.29%×0.46

CTMX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.0%▲+2.67%×0.19

= impliedVRDN realized, solidCTMX realized, hatchedOne scale, both sides: full bar = 34%× = |realized| ÷ impliedSource: market data

VRDNViridian Therapeutics, Inc.

25.29▲+2.49%· post 25.29

Mkt cap$2.8BRevenue$284,000Q2 FY26Revenue$71MFY25

CTMXCytomX Therapeutics, Inc.

2.23▼−4.70%· post 2.23

ClosedNov 2 '26

Mkt cap$509.9MRevenue$1MQ2 FY26Revenue$76MFY25

Compare

ClosedNov 2 '26

VRDNViridian Therapeutics, Inc.

CTMXCytomX Therapeutics, Inc.

25.29▲+2.49%post 25.29

Price

2.23▼−4.70%post 2.23

$2.8B

Mkt cap

$509.9M

Q2 FY26$284,000

Revenue

$1MQ2 FY26

FY25$71M

Revenue

$76MFY25

VRDN25.29▲+2.49%vsCTMX2.23▼−4.70%ClosedNov 2 '26